Palumbo Wealth Management LLC Purchases Shares of 25,330 Boston Scientific Corporation $BSX

Palumbo Wealth Management LLC purchased a new stake in shares of Boston Scientific Corporation (NYSE:BSX) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 25,330 shares of the medical equipment provider’s stock, valued at approximately $2,405,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of BSX. First American Trust FSB raised its position in Boston Scientific by 0.3% in the third quarter. First American Trust FSB now owns 80,908 shares of the medical equipment provider’s stock worth $7,899,000 after acquiring an additional 237 shares in the last quarter. Mufg Securities Americas Inc. grew its stake in shares of Boston Scientific by 21.9% in the 3rd quarter. Mufg Securities Americas Inc. now owns 39,957 shares of the medical equipment provider’s stock worth $3,901,000 after purchasing an additional 7,168 shares during the last quarter. Baldwin Investment Management LLC grew its stake in shares of Boston Scientific by 5.4% in the 3rd quarter. Baldwin Investment Management LLC now owns 13,145 shares of the medical equipment provider’s stock worth $1,283,000 after purchasing an additional 675 shares during the last quarter. AXQ Capital LP bought a new stake in shares of Boston Scientific in the 3rd quarter worth approximately $1,434,000. Finally, Compound Planning Inc. lifted its stake in Boston Scientific by 22.1% during the third quarter. Compound Planning Inc. now owns 13,445 shares of the medical equipment provider’s stock valued at $1,313,000 after purchasing an additional 2,436 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of BSX stock opened at $74.37 on Tuesday. The company has a market capitalization of $110.36 billion, a price-to-earnings ratio of 38.33, a P/E/G ratio of 1.03 and a beta of 0.67. Boston Scientific Corporation has a 1-year low of $72.69 and a 1-year high of $109.50. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. The stock’s fifty day simple moving average is $88.87 and its 200-day simple moving average is $96.32.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The firm had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same period last year, the company posted $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, sell-side analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at $2,396,580. This trade represents a 42.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on BSX shares. Weiss Ratings lowered shares of Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, February 4th. Evercore decreased their target price on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Oppenheimer decreased their price target on Boston Scientific from $125.00 to $100.00 and set an “outperform” rating for the company in a research report on Friday, January 16th. Finally, Morgan Stanley dropped their price target on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $108.36.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.